Translational Oncology Research Center

Translational Oncology Research Center’s Innovative Activities

Translational Oncology Research Center aims to be the regional hub for cancer research with its state-of-the-art equipment and highly skilled staff members. The center benefits from the well-equipped and resourceful laboratories to execute inventive and innovative ideas in cancer research, resulting in a number of discoveries.

Translational Oncology Research Center investigators have submitted several patent applications related to

  • Targeting lactate dehydrogenase C to improve treatment response to common anti-cancer drugs.
  • Therapeutic potential of lactate dehydrogenase C for immunotherapy.
  • Identification and therapeutic potential of mRNA and lncRNA-based signatures in the resistance of triple negative breast cancer (TNBC) to neoadjuvant chemotherapy.
Innovation Commercialization 2

Diabetes Research Center (DRC)

Innovation Activities of the DRC

  • Creating and developing intellectual property (IP) and commercial development.
  • Developing blood and urine-based tests for predicting the progression of diabetic kidney disease.
  • Developing dietary supplements for improved immune health and methods for treating COVID-19.
  • Generating induced pluripotent stem cells (iPSCs) with GLUT2 mutations.
  • Generating induced pluripotent stem cells (iPSCs) with FOXA2 deletion.
  • Establishing new human iPSC lines to study diabetes due to mutations in the glucokinase gene.
innovation-ndrc

Neurological Disorders Research Center (NDRC)

Innovation Activities of the NDRC

The innovative research efforts led by the NDRC investigators have resulted in a number of inventions that are impacting patient care. examples include:

  • Patent applications for antibodies directed against alpha-synucein linked to Parkinson’s disease.
  • Agreements with biopharmaceuticals (AFFiRiS, Idorsia, Herantis, and Lundbeck) to use in-house technologies.
  • Registration of QABY Biotech as a trademark with QF.
  • Licensing agreements with Abcam and Euroimmun to distribute in-house developed reagents.
  • The first AI Arabic digital phenotyping for social communication (a diagnostic tool for Autism).